Buy, Sell, or Hold: Questcor Pharmaceuticals
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether it's possible upside outweighs its risks. Let's take a look at Questcor Pharmaceuticals (NAS: QCOR) today and see why you might want to buy, sell, or hold it.
Founded in 1990 and based in Anaheim, Calif., Questcor has a market capitalization of about $1.6 billion. It's a biopharmaceutical company targeting conditions such as multiple sclerosis, nephrotic syndrome, collagen diseases, rheumatic disorders, and infantile spasms. One of its key products is its Acthar Gel, an injectible drug. Over the past year, Questcor shares have dropped 36%, leading some to wonder whether it's a bargain.
One reason to consider buying Questcor is its business. With the world's population growing, getting older, and living longer, demand for health-care products and services is likely to remain in demand.
Another plus is that unlike many biotech companies, Questcor actually has products on the market, generating revenue. Its flagship product, Acthar, is seeing its sales grow very rapidly. And Questcor isn't relying just on that. It's moving into rheumatology now, too.
Lots of numbers in its financial statements look good: Revenue and earnings have been growing at accelerating rates, recently topping 80%. Free cash flow has gone from a loss of $14 million in 2006 to a positive $40 million in 2009 to $166 million in the past 12 months. Profit margins were very sizable even a few years ago, but they've been getting even stronger, with net margins recently at 39%. Returns on assets, equity, and invested capital: all hefty and growing.
Questcor's brand-new dividend is another attraction, recently yielding a solid 3.1%. There are only a few dozen dividends of that size or greater among health-care companies. You can certainly do better, such as via PDL BioPharma's (NAS: PDLI) hefty 8% yield, but its future is a bit uncertain, as the company's revenue growth has slowed and some valuable patents will be expiring soon.
Then there's valuation. With the stock down so much lately, it looks attractive. Its recent P/E ratio of 10 is about half its five-year average P/E, and its forward P/E of 7 is about half of that of the S&P 500.
Of course, all is not completely rosy for this company. The stock was just about slashed in half on a single day in September, when insurer Aetna (NYS: AET) said it would limit coverage for Acthar. It's true that Aetna represents only about 5% of Acthar sales, but its decision has many wondering whether other insurers will follow suit, which could be disastrous. The company, so far, is maintaining that this decision won't have much of a material effect on its business. It might be right -- UnitedHealth Group (NYS: UNH) , for example, recently tweaked its Acthar policies in only minor ways.
Another worry is a recent investigation into Questcor's marketing practices, accompanied by some lawsuits. Even if the company emerges victorious, these kinds of things can sap its time, energy, and resources -- like cash. My colleague Keith Speights has noted, for example, that just settling can be costly, with Amgen (NAS: AMGN) paying a $780 million settlement last year, and Pfizer (NYS: PFE) paying $2.3 billion.
Those factors reflect another: volatility. If you can't stomach sharp swings in a stock's price, perhaps look elsewhere.
The role of Acthar in Questcor's revenue is another worry: If it takes a big hit, so will the company. It's always good to have a more diversified revenue base, to dilute risks. Indeed, news of a new generic competitor recently knocked the stock down some. And other competition exists, too -- it another, better drug for MS comes along, that will be bad for Questcor.
Given the reasons to buy or sell Questcor, it's not unreasonable to decide to just hold off on it. You might want to wait for the investigation into its marketing practices to be resolved, and for it to be clear whether other insurers will limit Acthar's reimbursement. You might want to see a wider range of products in its stable, too.
I'm holding off on Questcor for now, but I'm intrigued as well. Everyone's investment calculations are different, though. Do your own digging and see what you think. Questcor may perform spectacularly in the coming years, but remember that there are plenty of compelling stocks out there.
Questcor is one of the most debated names in all of biotech. Acthar is growing at a torrid pace -- and minting money in the process. But is it worth the risk? See what our analysts think in our brand-new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.
The article Buy, Sell, or Hold: Questcor Pharmaceuticals originally appeared on Fool.com.Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter, owns shares of PDL BioPharma. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend PDL BioPharma and UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.